<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660332</url>
  </required_header>
  <id_info>
    <org_study_id>H-16036538</org_study_id>
    <nct_id>NCT03660332</nct_id>
  </id_info>
  <brief_title>The Effect of an Acute Increase in Plasma IL-6 on Glucose Tolerance When a Meal is Administered Intraduodenally</brief_title>
  <acronym>DUIL-6</acronym>
  <official_title>The Effect of an Acute Increase in Plasma IL-6 on Glucose Tolerance When a Meal is Administered Intraduodenally</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate and clarify whether the effect of IL-6 on glucose
      tolerance and insulin secretion are secondary to the changes in gastric emptying.

      The literature provides no information regarding a role for interleukin-6 (IL-6) in the
      regulation of beta cell function (glucose or meal-stimulated insulin secretion) in humans.
      Previous studies infusing IL-6 into humans have primarily focused on insulin action and the
      effects on peripheral insulin sensitivity whereas a potential effect on insulin secretion has
      been neglected.

      We have demonstrated that an acute increase in IL-6, obtained by a single bolus of IL-6,
      potentiated glucose-induced insulin secretion in a glucagon-like peptide-1 (GLP-1) dependent
      manner in mice1. In mice, IL-6 enhanced insulin secretion in a dose- and glucose-dependent
      manner, along with increasing concentrations of GLP-1. Interleukin-6 had no effect on insulin
      secretion in GLP-1 receptor knock-out mice or in mice treated with the GLP-1 receptor
      antagonist. Thus, in mice, GLP-1 has proven an essential mediator of IL-6 actions on beta
      cell function.

      Importantly, a single bolus of IL-6 also significantly increased glucose-stimulated insulin
      secretion in several mouse models of obesity and diabetes (diet-induced obesity, the ob/ob
      and the db/db mouse).

      Own data show that an infusion of IL-6 causes a significant delay in the rate of gastric
      emptying (GE) after a mixed meal in healthy young men. Data showed that this delay in GE is
      associated with much improved glucose tolerance and insulin secretion (unpublished data).

      In the present study we wish to investigate whether the beneficial effects of IL-6 on
      postprandial glucose tolerance and insulin secretion are dependent on a delay in gastric
      emptying. We will bypass the ventricle and infuse a mixed meal directly into the duodenum of
      healthy young men.

      This study has the potential to show that the known effect of IL-6 on postprandial glucose
      tolerance is dependent on a delayed GE.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">April 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The paracetamol uptake</measure>
    <time_frame>0-14 days</time_frame>
    <description>paracetamol blood levels (mmol/l) on both study days. The paracetamol absorbance will be compared between the 2 study days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GLP-1 secretion</measure>
    <time_frame>0-14 days</time_frame>
    <description>Active GLP-1 blood levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon secretion</measure>
    <time_frame>0-14 days</time_frame>
    <description>Glucagon blood levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>0-14</time_frame>
    <description>Insulin blood levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>0-14</time_frame>
    <description>Plasma glucose levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Postprandial Glucose Homeostasis</condition>
  <arm_group>
    <arm_group_label>IL-6 infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy young men will receive IL-6 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy young men will receive saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infusion of a liquid meal intraduodenally</intervention_name>
    <description>Infusion of IL-6/NaCL before a liquid meal intraduodenally</description>
    <arm_group_label>IL-6 infusion</arm_group_label>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and ≤ 35 years

          -  Healthy (based on screening)

        Exclusion Criteria:

          -  Smoking

          -  BMI &lt; 18 and &gt; 25 kg/m2

          -  Evidence of severe thyroid, liver, lung, heart or kidney disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente K Pedersen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>CFAS, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Louise Lang Lehrskov</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

